



FOR IMMEDIATE RELEASE

## **Cancer Prevention Pharmaceuticals to Present at the 29<sup>th</sup> Annual Piper Jaffray Healthcare Conference**

### ***CEO to give update on clinical pipeline and lead drug CPP-1X***

TUCSON, Arizona, November 21, 2017—Cancer Prevention Pharmaceuticals (CPP), a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29<sup>th</sup> Annual Healthcare Conference on November 28, 7:50-8:10 am ET at the Lotte New York Palace in New York City (Track Seven: Kennedy 2, 4th floor). CPP CEO Jeff Jacob will give an update on the company’s pipeline including its lead Phase 3 drug CPP-1X/sul for treatment of familial adenomatous polyposis (FAP). CPP recently engaged Piper Jaffray to support its anticipated financing activities.

FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. In June, an Independent Data Monitoring Committee (IDMC) recommended continuation of the Phase 3 trial following a planned interim futility analysis. In September, the U.S. Food and Drug Administration granted CPP-1X/sul “fast track” status, potentially speeding regulatory approval and commercialization.

In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) that grants Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sul in North America. Sucampo recently highlighted CPP-1X/sul during their 2017 R&D Day in New York City.

For more information on the FAP clinical trial (CPP FAP-310), please visit: <https://clinicaltrials.gov/ct2/show/NCT01483144>.

#### **About Cancer Prevention Pharmaceuticals, Inc.**

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the FAP-310 trial, CPP is co-sponsoring with the National Cancer Institute (NCI) and SWOG a large Phase 3 trial in colon cancer survivors. CPP is also working collaboratively with nonprofit groups to support their clinical trials in neuroblastoma, gastric cancer, and early-onset type 1 diabetes. CPP is located in Tucson, Arizona. For more information, please visit <http://canprevent.com>.

For more information on the clinical trial (CPP FAP-310), please visit: <https://clinicaltrials.gov/ct2/show/NCT01483144>.



*This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the benefits of Fast Track Status. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.*

**Investor Contact:** Chris Richied, CFO, Cancer Prevention Pharmaceuticals, Inc, +1.520.908.7774

**Media Contact:** Christine Brannen, Cancer Prevention Pharmaceuticals, Inc.,  
press@canprevent.com, +1.520.908.7774

###